Philip J. Lowe - Concepedia

Author

Philip J. Lowe

Novartis (Switzerland)ORCID

Also Known As

Joerg Lippert, Lowe, P, P J Lowe, P Lowe, P. J. LOWE, P. J. Lowe, P. J. M. Lowe, P. LOWE, P. Lowe, P.J. Lowe

101

Publications

4.2K

Citations

H-Index

Concepts

All Affiliations

Novartis (Switzerland)University of Birmingham University at Buffalo, State University of New York Novartis Institutes for BioMedical Research United States Department of Veterans Affairs

About

Philip J. Lowe is an author at Novartis (Switzerland) specializing in medicine, pharmacology, and liver physiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	16	825
2	Health Sciences	5	5	347
3	Arts	1	1	19
4	Natural Sciences	1	1	179
5	Public Health	1	1	13

Philip J. Lowe

Publications

Citations

H-Index

Page 1

	Year	Citations
In vivo regulation of interleukin 1β in patients with cryopyrin-associated periodic syndromes Helen J. Lachmann, Philip J. Lowe, Sandra Daniela Felix, The Journal of Experimental Medicine	2009	291
Pharmacokinetics, pharmacodynamics and safety of <scp>QGE</scp>031 (ligelizumab), a novel high‐affinity anti‐IgE antibody, in atopic subjects Jonathan Arnold A. P., I. Bottoli, Andrej Skerjanec, Clinical & Experimental Allergy	2014	239
Substitution of antibodies and receptors with molecularly imprinted polymers in enzyme-linked and fluorescent assays Sergey A. Piletsky, Elena Piletska, Alessandra Bossi, Biosensors and Bioelectronics Immunocytochemical TechniqueBiochemistryFluorescent AssaysNatural SciencesBioanalysis	2001	179
A mechanism‐based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab Naoto Hayashi, Yuko Tsukamoto, William M. Sallas, British Journal of Clinical Pharmacology	2006	168
Calcitonin and Insulin in Isobutylcyanoacrylate Nanocapsules: Protection Against Proteases and Effect on Intestinal Absorption in Rats Philip J. Lowe, Cathy S Temple Journal of Pharmacy and Pharmacology	1994	163
Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE‐mediated) asthma Philip J. Lowe, Stacey Tannenbaum, Aurélie Gautier, British Journal of Clinical Pharmacology	2009	163
Membrane lipid composition and susceptibility to bile salt damage R. Coleman, Philip J. Lowe, David C. Billington Biochimica et Biophysica Acta (BBA) - Biomembranes BiochemistryBiliary TractLiver PhysiologyLipidsLipid Movement	1980	135
Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses Gail M. Gauvreau, P. Jonathan, Louis‐Philippe Boulet, Journal of Allergy and Clinical Immunology AsthmaVersus OmalizumabAllergyMultiple DosesAllergy Medicine	2016	135
Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations Raymond G. Slavin, Caterina Ferioli, Stacey Tannenbaum, Journal of Allergy and Clinical Immunology AsthmaPharmacokinetic ConcentrationsOmalizumab WithdrawalAllergyAllergy Medicine	2009	133
Omalizumab decreases IgE production in patients with allergic (IgE‐mediated) asthma; PKPD analysis of a biomarker, total IgE Philip J. Lowe, Didier Renard British Journal of Clinical Pharmacology	2011	132

Page 1